Abstract
Indications for TF-TAVI (transfemoral transcatheter aortic valve implantation) are rapidly changing according to increasing evidence from randomized controlled trials. Present trials document the non-inferiority or even superiority of TF-TAVI in intermediate-risk patients (STS-Score 4–8%) as well as in low-risk patients (STS-Score < 4%). However, risk scores exhibit limitations and, as a single criterion, are unable to establish an appropriate indication of TF-TAVI vs transapical TAVI vs SAVR (surgical aortic valve replacement). The ESC (European Society of Cardiology)/EACTS (European Association for Cardio-Thoracic Surgery) guidelines 2017 and the German DGK (Deutsche Gesellschaft für Kardiologie)/DGTHG (Deutsche Gesellschaft für Thorax-, Herz- und Gefäßchirurgie) commentary 2018 offer a framework for the selection of the best therapeutic method, but the individual decision is left to the discretion of the heart teams. An interdisciplinary TAVI consensus group of interventional cardiologists of the ALKK (Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte e.V.) and cardiac surgeons has developed a detailed consensus on the indications for TF-TAVI to provide an up-to-date, evidence-based, comprehensive decision matrix for daily practice. The matrix of indication criteria includes age, risk scores, contraindications against SAVR (e.g., porcelain aorta), cardiovascular criteria pro TAVI, additional criteria pro TAVI (e.g., frailty, comorbidities, organ dysfunction), contraindications against TAVI (e.g., endocarditis) and cardiovascular criteria pro SAVR (e.g., bicuspid valve anatomy). This interdisciplinary consensus may provide orientation to heart teams for individual TAVI-indication decisions. Future adaptations according to evolving medical evidence are to be expected.
Graphic abstract
Interdisciplinary consensus on indications for transfemoral transcatheter aortic valve implantation (TF-TAVI).
Similar content being viewed by others
References
Deutscher Herzbericht (2018) Deutsche Herzstiftung e.V., Frankfurt am Main. https://www.herzstiftung.de/herzbericht. Accessed 2 June 2019
IQTIG Qualitätsreport (2017) https://iqtig.org/berichte/qualitaetsreport/. Accessed 2 June 2019
Leon MB, Smith CR, Mack M et al (2010) Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 363:1597–1607
Kapadia SR, Leon MB, Makkar RR et al (2015) 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1B): a randomized controlled trial. Lancet 385:2485–2491
Kodali SK, Williams MR, Smith CR et al (2012) Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 366:1686–1695
Mack MJ, Leon MB, Smith CR et al (2015) 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1A): a randomized controlled trial. Lancet 385:2477–2484
Adams DH, Popma JJ, Reardon MJ et al (2014) Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 370:1790–1798
Deeb GM, Reardon MJ, Chetcuti S et al (2016) 3-year outcomes in high-risk patients who underwent surgical or transcatheter aortic valve replacement. J Am Coll Cardiol 67:2565–2574
Leon MB, Smith CR, Mack MJ et al (2016) Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 374:1609–1620
Thourani VH, Kodali S, Makkar RR et al (2016) Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet 387:2218–2225
Reardon MJ, Van Mieghem NM, Popma JJ et al (2017) Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 376:1321–1331
Mack MJ, Leon MB, Thourani VH et al (2019) Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 380:1695–1705
Popma JJ, Deeb GM, Yakubov SJ et al (2019) Transcatheter aortic valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 380:1706–1715
Baumgartner H, Falk V, Bax JJ et al (2017) 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J 38:2739–2791
Nishimura RA, Otto CM, Bonow RO et al (2017) 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 135:e1159–e1195
Kötting J, Schiller W, Beckmann A, Schäfer E, Döbler K, Hamm C, Veit C, Welz A (2013) German Aortic Valve Score: a new scoring system for prediction of mortality related to aortic valve procedures in adults. Eur J Cardiothorac Surg 43:971–977
Kuck KH, Eggebrecht H, Elsässer A et al (2016) Qualitätskriterien zur Durchführung der kathetergestützten Aortenklappenimplantation (TAVI). Kardiologe 10:282–300
Rosenhek R, Iung B, Tornos P et al (2012) ESC Working Group on Valvular Heart Disease Position Paper: assessing the risk of interventions in patients with valvular heart disease. Eur Heart J 33:822–828
Vahanian A, Alfieri O, Andreotti F et al (2012) Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 33:2451–2496
EuroSCORE II Calculator. http://www.euroscore.org/calc.html. Accessed 2 June 2019
Logistic EuroSCORE I Calculator. http://www.euroscore.org/calcge.html. Accessed 2 June 2019
STS Score Calculator. http://riskcalc.sts.org/stswebriskcalc/#/calculate. Accessed 2 June 2019
Otto CM, Kumbhani D, Alexander KP et al (2017) 2017 ACC expert consensus decision pathway for transcatheter aortic valve replacement in the management of adults with aortic stenosis. J Am Coll Cardiol 69:1313–1346
Bonow RO, Brown AS, Gillam LD, Kapadia SR, Kavinsky CJ et al (2017) ACC/AATS/AHA/ASE/EACTS/HVS/SCA/SCAI/SCCT/SCMR/STS 2017 appropriate use criteria for the treatment of patients with severe aortic stenosis. J Am Coll Cardiol 70:2566–2598
Baumgartner H, Eggebrecht H, Hamm C, Haude M, Ince H, Kuck K-H, im Auftrag des Vorstands der DGK, Cremer J, Diegeler A, Welz A, Beyersdorf F, Walther T, Falk V, im Auftrag des Vorstands der DGTHG (2018) Kommentar zur ESC/EACTS-Leitlinie von 2017 zum Management von Herzklappenfehlern. Kardiologe 12:184–193
Grover FL, Vemulapalli S, Carroll JD et al (2017) 2016 annual report of the Society of Thoracic Surgeons/American College of Cardiology transcatheter valve therapy registry. J Am Coll Cardiol 69:1215–1230
Hamm CW, Möllmann H, Holzhey D, Beckmann A, Veit C, Figulla HR, Cremer J, Kuck KH, Lange R, Zahn R, Sack S, Schuler G, Walther T, Beyersdorf F, Böhm M, Heusch G, Funkat AK, Meinertz T, Neumann T, Papoutsis K, Schneider S, Welz A, Mohr FW, GARY-Executive Board (2014) The German Aortic Valve Registry (GARY): in-hospital outcome. Eur Heart J 35:1588–1598
Walther T, Hamm CW, Schuler G, Berkowitsch A et al (2015) Perioperative results and complications in 15.964 transcatheter aortic valve replacements: prospective data from the GARY registry. J Am Coll Cardiol 65:2173–2180
Gaede L, Blumenstein J, Liebetrau C et al (2017) Outcome after transvalvular transcatheter aortic valve implantation in 2016. Eur Heart J. https://doi.org/10.1093/eurheartj/ehx688
Thyregod HGH, Ihlemann N, Jorgensen TH et al (2019) Five-year clinical and echocardiographic outcomes from the Nordic Aortic Valve Intervention (NOTION) randomized clinical trial in lower surgical risk patients. Circulation. https://doi.org/10.1161/circulationaha.118.036606
Waksman R, Rogers T, Torguson R et al (2018) Transcatheter aortic valve replacement in low-risk patients with symptomatic severe aortic stenosis. J Am Coll Cardiol 72:2095–2105
Waksman R, Corso PJ, Torguson R et al (2019) Transcatheter aortic valve replacement in low-risk patients: one-year results from the LRT trial. JACC Cardiovasc Interv 72:2095. https://doi.org/10.1016/j.jcin.2019.03.002
Otto CM (2019) Informed shared decisions for patients with aortic stenosis. N Engl J Med 380:1769–1770
Siontis GCM, Overtchouk P, Cahill TJ et al (2019) Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. Eur Heart J 37:3503. https://doi.org/10.1093/eurheartj/ehz275
Capodanno D, Petronio AS, Prendergast B et al (2017) Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 38:3382–3390
Lancelotti P, Martinez C, Radermecker M (2019) The long quest for the holy grail in transcatheter aortic bioprosthesis. J Am Coll Cardiol 73:554–558
Barbanti M, Petronio AS, Ettori F et al (2015) 5-Year outcomes after transcatheter aortic valve implantation with CoreValve prosthesis. J Am Coll Cardiol Interv 8:1084–1091
Eltchaninoff H, Durand E, Avinée G, Tron C et al (2018) Assessment of structural valve deterioration of transcatheter aortic bioprosthetic balloon-expandable valves using the new European consensus definition. EuroIntervention. https://doi.org/10.4244/eij-d-18-00015
Blackman DJ, Saraf S, MacCarthy PA et al (2019) Long-term durability of transcatheter aortic valve prostheses. J Am Coll Cardiol 73:537–545
Søndergaard L, Ihlemann N, Capodanno D et al (2019) Durability of transcatheter and surgical bioprosthetic aortic valves in patients at lower surgical risk. J Am Coll Cardiol 73:546–553
Puri R, Iung B, Cohen DJ et al (2016) TAVI or no TAVI: identifying patients unlikely to benefit from transcatheter aortic valve implantation. Eur Heart J 37:2217–2225
Thourani VH, Borger MA, Holmes D et al (2017) Transatlantic commentary on transcatheter aortic valve replacement. J Thorac Cardiovasc Surg 154:7–21
GBA-Richtlinie zu minimalinvasiven Herzklappeninterventionen BAnz AT 24.07.2015 B6
Chambers JB, Prendergast B, Iung B, Rosenhek R, Zamorano JL et al (2017) Standards defining a “Heart Valve Centre”: ESC working group on valvular heart disease and European Association for cardiothoracic surgery viewpoint. Eur Heart J 38:2177–2183
Carabello BA (2017) Valve-in-valve TAVR. J Am Coll Cardiol 69:2263–2265
Deeb GM, Chetcuti SJ, Reardon MJ et al (2017) 1-Year results in patients undergoing transcatheter aortic valve replacement with failed surgical bioprostheses. J Am Coll Cardiol Interv 10:1034–1044
Vahl TP, Kodali SK, Leon MB (2016) Transcatheter aortic valve replacement 2016. J Am Coll Cardiol 67:1472–1487
Webb JG, Mack MJ, White JM et al (2017) Transcatheter aortic valve implantation within degenerated aortic surgical bioprostheses. J Am Coll Cardiol 69:2253–2262
Neumann FJ, Sousa-Uva M, Ahlsson A et al (2018) 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 40:87. https://doi.org/10.1093/eurheratj/ehy394
Colombo A, Latib A (2014) Bicuspid aortic valve: any room for TAVR? J Am Coll Cardiol 64:2340–2342
Frangieh AH, Kasel AM (2017) TAVI in bicuspid aortic valves “made easy”. Eur Heart J 38:1177–1181
Guyton RA, Padala M (2016) Transcatheter aortic valve replacement in bicuspid aortic stenosis. Early success, but concerning red flags. J Am Coll Cardiol Interv 9:825–827
Mylotte D, Lefevre T, Søndergaard L et al (2014) Transcatheter aortic valve replacement in bicuspid aortic valve disease. J Am Coll Cardiol 64:2330–2339
Perlman GY, Blanke P, Dvir D et al (2016) Bicuspid aortic valve stenosis: favorable early outcomes with a next-generation transcatheter heart valve in a multicenter study. J Am Coll Cardiol Interv 9:817–824
Afilalo J, Lauck S, Kim DH, Lefèvre T, Piazza N, Lachapelle K et al (2017) Frailty in older adults undergoing aortic valve replacement: the FRAILTY-AVR study. J Am Coll Cardiol 70:689–700
Prados-Torres A, Calderón-Larranaga A, Hancco-Saavedra J et al (2014) Multimorbidity patterns: a systematic review. J Clin Epidemiol 67:254–266
Acknowledgements
Interdisciplinary Working Group members: W. von Scheidt, A. Welz, M. Pauschinger, T. Fischlein, V. Schächinger, H. Treede, R. Zahn, M. Hennersdorf; TAVI-Consensus-Group members: J. M. Albes, R. Bekeredjian, M. Beyer, J. Brachmann, C. Butter, L. Bruch, H. Dörge, W. Eichinger, U. F. W. Franke, N. Friedel, T. Giesler, R. Gradaus, R. Hambrecht, M. Haude, H. Hausmann, M. P. Heintzen, W. Jung, S. Kerber, H. Mudra, T. Nordt, L. Pizzulli, F.-U. Sack, S. Sack, B. Schumacher, G. Schymik, U. Sechtem, C. Stellbrink, C. Stumpf, H. M. Hoffmeister. Members of the ALHK (Arbeitsgemeinschaft Leitende Herzchirurgische Krankenhausärzte e.V.): T. Fischlein, W. Eichinger, U. F. W. Franke, H. Hausmann, F.-U. Sack.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
von Scheidt, W., Welz, A., Pauschinger, M. et al. Interdisciplinary consensus on indications for transfemoral transcatheter aortic valve implantation (TF-TAVI). Clin Res Cardiol 109, 1–12 (2020). https://doi.org/10.1007/s00392-019-01528-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00392-019-01528-5